TLDR Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.
A 26-year-old male with recalcitrant dissecting cellulitis of the scalp (DCS) showed significant clinical improvement after a short course of upadacitinib, a Janus kinase (JAK) inhibitor. Previous treatments, including topical antimicrobials, oral antibiotics, corticosteroids, and intralesional triamcinolone injections, had limited success. Upadacitinib reduced the patient's pain, pustular draining, and bleeding, and improved his quality of life. This case suggests that JAK inhibitors may be a promising therapy for refractory DCS, a condition with few effective treatment options.
2 citations
,
March 2023 in “Frontiers in medicine” A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.
48 citations
,
January 2014 in “Dermatology Online Journal” New treatments for Dissecting cellulitis show promise, but more research is needed to understand the disease and establish a standard treatment plan.
2 citations
,
March 2023 in “Frontiers in medicine” A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.
May 2025 in “Orphanet Journal of Rare Diseases” TNF-α blockers and IL inhibitors improve symptoms in most patients with severe scalp condition, but more research is needed.
May 2025 in “Journal of Inflammation Research” A combination of ixekizumab and tofacitinib successfully treated severe scalp cellulitis, leading to hair regrowth.
4 citations
,
January 2025 in “JAAD reviews.” Janus kinase inhibitors are promising for treating scarring alopecia, but more research is needed for safety and personalized treatments.
May 2022 in “Journal of the Dermatology Nurses' Association” The convention highlighted the importance of comprehensive patient care and early diagnosis in dermatology.
